By Charles Bankhead, Staff Writer, MedPage Today
Published: March 30, 2010
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner |  |
|
BARCELONA -- Breast cancer patients on concomitant beta-blocker therapy had significantly better outcomes compared with other patients, including a reduced risk of metastasis and improved disease-specific survival, data from an observational study showed.
Patients taking beta blockers had a 57% reduction in the risk of distant metastasis and a 71% reduction in the risk of breast cancer-specific death, as compared with patients on other antihypertensive agents or no antihypertensive therapy, Des Powe, PhD, reported here at the European Breast Cancer Conference. |
|
No comments:
Post a Comment